Drugs / ACALISIB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01705847 | Nov 2012 → May 2016 | lymphoma | Gilead Sciences | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACALISIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4303323 ↗ |
| Known as | CAL-120 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4303323 ↗ |
| Known as | GS-9820 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01705847 ↗ |
| Action | Inhibit | “PI3-kinase p110-delta subunit inhibitor” CHEMBL4303323 ↗ |
| Modality | Small molecule | — CHEMBL4303323 ↗ |
| Route | Oral | “administered orally” NCT01705847 ↗ |
| Target | PIK3CD | “PI3-kinase p110-delta subunit inhibitor” CHEMBL4303323 ↗ |